Spyre Therapeutics, Inc.
Price Action
Technical Summary
STAGE 2 UPTRENDSpyre Therapeutics, Inc. is in a confirmed Stage 2 uptrend, with price holding above all major moving averages and trend structure remaining intact. Relative strength is leading (RS Rating: 97), indicating clear outperformance against the broad market. Earnings contraction of 469% provides fundamental context to the price action. Investors should exercise caution due to high volatility (70% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $82.16 | +9.73% | ABOVE |
| 50 SMA | $76.35 | +18.09% | ABOVE |
| 100 SMA | $60.24 | +49.67% | ABOVE |
| 150 SMA | $50.82 | +77.42% | ABOVE |
| 200 SMA | $43.14 | +109.01% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is SYRE in an uptrend right now?
SYRE has a trend score of 4/4 based on Minervini's Stage Analysis. Yes, SYRE is in a Stage 2 uptrend with price above all major moving averages (50, 100, 150, 200 SMA) properly stacked.
Is SYRE overbought or oversold?
SYRE's RSI (14) is 58. The stock is in neutral territory, neither overbought nor oversold.
Is SYRE outperforming the market?
SYRE has a Relative Strength (RS) Rating of 97 out of 99. Yes, SYRE is a market leader, outperforming 97% of all stocks over the past 12 months.
Where is SYRE in its 52-week range?
SYRE is trading at $90.16, which is 88% of its 52-week high ($102.06) and 86% above its 52-week low ($14.00).
How volatile is SYRE?
SYRE has a Beta of 1.96 and 52-week volatility of 70%. It's more volatile than the S&P 500 - expect bigger swings.